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of the three studies showed that microcurrent therapy and placebo significantly reduced pain but one was not
more efficacious than the other. The other study found microcurrent therapy was more efficacious than
placebo. All studies received a GRADE quality of evidence rating of low.
Conclusion: At this time there is not enough high quality evidence to say with any certainty that
microcurrent therapy is more efficacious than placebo in reducing pain caused by diabetic neuropathy. The
three RCTs that have been performed to date, have been small and have conflicting results. The results do
indicate a large placebo effect which should not be discounted when considering the utility of microcurrent
therapy.
Degree Type
Capstone Project
Degree Name
Master of Science in Physician Assistant Studies
First Advisor
Robert P. Rosenow, Pharm.D., O.D.
Second Advisor
Annjanette Sommers PA-C, MS
Keywords
microcurrent, diabetic neuropathy
Subject Categories
Medicine and Health Sciences
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/290
Rights
Terms of use for work posted in CommonKnowledge.
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/290
Copyright and terms of use
If you have downloaded this document directly from the web or from CommonKnowledge, see the
“Rights” section on the previous page for the terms of use.
If you have received this document through an interlibrary loan/document delivery service, the
following terms of use apply:
Copyright in this work is held by the author(s). You may download or print any portion of this document
for personal use only, or for any use that is allowed by fair use (Title 17, §107 U.S.C.). Except for personal
or fair use, you or your borrowing library may not reproduce, remix, republish, post, transmit, or
distribute this document, or any portion thereof, without the permission of the copyright owner. [Note:
If this document is licensed under a Creative Commons license (see “Rights” on the previous page)
which allows broader usage rights, your use is governed by the terms of that license.]
Inquiries regarding further use of these materials should be addressed to: CommonKnowledge Rights,
Pacific University Library, 2043 College Way, Forest Grove, OR 97116, (503) 352-7209. Email inquiries
may be directed to:. copyright@pacificu.edu
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/290
 
 
NOTICE TO READERS 
 
This work is not a peer-reviewed publication.  The Master’s Candidate author of this 
work has made every effort to provide accurate information and to rely on authoritative 
sources in the completion of this work.  However, neither the author nor the faculty 
advisor(s) warrants the completeness, accuracy or usefulness of the information provided 
in this work.  This work should not be considered authoritative or comprehensive in and 
of itself and the author and advisor(s) disclaim all responsibility for the results obtained 
from use of the information contained in this work.  Knowledge and practice change 
constantly, and readers are advised to confirm the information found in this work with 
other more current and/or comprehensive sources. 
 
The student author attests that this work is completely his/her original authorship and that 
no material in this work has been plagiarized, fabricated or incorrectly attributed.         
 
1 
 
 
The Efficacy of Microcurrent Transcutaneous Electric Nerve 
Stimulation as Compared to Placebo in Reducing Pain Caused by 
Diabetic Neuropathy: A Systematic Review 
 
 
 
Joe Russell 
 
 
 
 
 
A Clinical Graduate Project Submitted to the Faculty of the  
School of Physician Assistant Studies 
Pacific University 
Hillsboro, OR  
For the Masters of Science Degree, August 2012 
 
Faculty Advisor: Dr. Rosenow 
Clinical Graduate Project Coordinator: Annjanette Sommers, PA-C, MS 
 
 
2 
 
Biography 
Joe Russell is a native of Oregon where he majored in Biology at Oregon State University. He 
worked as an EMT-Basic in Eugene, Oregon before starting PA school at Pacific University.  
3 
 
 
Abstract   
 
Background:  Pain caused by diabetic neuropathy is a common complication in diabetic 
patients. Microcurrent therapy is currently being used as an alternative treatment option 
for painful diabetic neuropathy, yet little research has been done to date on the efficacy of 
this treatment option in randomized controlled trials as compared to placebo. This 
systematic review was performed because there is no general consensus regarding the 
efficacy of this appealing treatment option for painful diabetic neuropathy 
 
Method:  An exhaustive literature search using Medline, Cinahl, Evidence-Based 
Medicine Reviews Multifile, and Google Scholar was performed. The following search 
terms with common synonyms were used: microcurrent and diabetic neuropathy. Only 
randomized controlled trials were used.  
 
Results:  Three articles were found that addressed the question of interest and met all 
eligibility criteria. Two of the three studies showed that microcurrent therapy and placebo 
significantly reduced pain but one was not more efficacious than the other.  The other 
study found microcurrent therapy was more efficacious than placebo.  All studies 
received a GRADE quality of evidence rating of low.  
 
Conclusion:  At this time there is not enough high quality evidence to say with any 
certainty that microcurrent therapy is more efficacious than placebo in reducing pain 
caused by diabetic neuropathy. The three RCTs that have been performed to date, have 
been small and have conflicting results. The results do indicate a large placebo effect 
which should not be discounted when considering the utility of microcurrent therapy. 
 
Keywords:  Microcurrent, diabetic neuropathy. 
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The Efficacy of Microcurrent Transcutaneous Electric Nerve Stimulation as 
Compared to Placebo in Reducing Pain Caused by Diabetic Neuropathy: A 
Systematic Review 
BACKGROUND 
 Pain caused by diabetic neuropathy is a common complication in diabetic 
patients. Between 1980 and 2010 the CDC reports the number of people with diabetes in 
the U.S.  had increased from 5.6 million to  20.9 million. Among these individuals the 
rate of neuropathy is steadily increasing.1 Pharmacological treatments have had some 
success in treating pain caused by diabetic neuropathy2 but because of side effects non-
pharmacological treatments are appealing to both patients and healthcare providers. 
Transcutaneous electric nerve stimulation (TENS) is one such treatment option. More 
recently a different form of TENS using microamperes instead of milliamperes called 
microcurrent therapy or microcurrent transcutaneous electric nerve stimulation (MTENS) 
has re-emerged since it fell out of favor with the AMA in the early part of the 20th 
century. The lack of harmful side effects associated with MTENS make it a potentially  
important option for patients who struggle with chronic pain caused by diabetic 
neuropathy and either do not respond to other treatments or do not wish to use 
pharmacologic treatment. One small study3 showed that microccurrent therapy reduced 
the pain of diabetic neuropathy significantly, but in this study there was no control group 
to use as a comparison. Researchers have demonstrated that microcurrent therapy can 
increase ATP generation and protein synthesis in rats which may have important 
implications for wound healing.4 Its use in treating other ailments such as tendinitis has 
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also been explored.5 Microcurrent therapy is currently being used as an alternative 
treatment option for painful diabetic neuropathy, yet little research has been done to date 
on the efficacy of this treatment option in randomized controlled trials as compared to 
placebo. This systematic review was performed because there is no general consensus 
regarding the efficacy of this appealing treatment option for painful diabetic neuropathy. 
METHODS 
 An exhaustive literature search using Medline, Cinahl, Evidence-Based Medicine 
Reviews Multifile, and Google Scholar was performed. The search terms used in all 
databases were microcurrent and diabetic neuropathy. In addition electrical stimulation, 
microampere, and Neuropathic Pain Scale were used to broaden the search. The limits 
English Language, Humans, and exclude Medline records were applied, when applicable, 
to help focus the search. Articles were screened by title, abstract, and/or review of the full 
text for relevance. The references of relevant articles were also reviewed for eligible 
studies.  
 
Eligibility Criteria  
 There were 5 inclusion criteria for the search: 1) The study must be a randomized 
controlled trial (RCT); 2) patients must have been adults who were diagnosed with 
diabetic peripheral neuropathy; 3) the electrotherapy used microamperes; 4) a control 
group was used; 5) pain was used as an endpoint.  
 Exclusion criteria included: 1) Electrical stimulation of the central nervous system 
was used; 2) Concomitant therapies were used along with microcurrent therapy in such a 
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way that attributing the results to microcurrent therapy alone would be difficult; 3) 
Electrical stimulation used the traditional milliampere intensity setting.  
 
 Literature appraisal and evidence grading—A thorough appraisal was done to 
evaluate each article for individual strengths and weaknesses using a form which 
addressed validity, magnitude and precision of results, and implications for clinicians and 
researchers. Each article was given a final quality rating according to the GRADE 
system.6  This process is described in the discussion section and summarized in Tables I 
and II. 
 
RESULTS 
 A total of 585 studies were screened for relevance. Three articles7-9 were found 
that met the inclusion and exclusion criteria. The first article by Gossrau et al7 is titled 
Microcurrent transcutaneous electric nerve stimulation in painful diabetic neuropathy: A 
randomized placebo-controlled study and was published in 2011. This study was a small, 
single blinded, RCT that administered 30-40 microamperes transcutaneously to the legs 
of 21 patients 3 times a week for 30 minutes a day over a 4 week period.  Randomization 
was not described. The smoking status of participants was not reported. All procedures 
were exactly duplicated for the 19 patients who constituted the control group except the 
leads were not connected to the machine. Multiple subjective outcomes were recorded 
but the study defined a successful treatment as at least a 30% reduction in Neuropathic 
Pain Score (NPS). All outcomes were measured at the start of the trial, after 4 weeks of 
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therapy, and 4 weeks after therapy was completed. No significant difference was found 
between the treatment group and the control group in any of the outcomes measured. No 
adverse side-effects were noted in any of the patients although in both groups some 
patients reported a pleasant warm sensation in their legs. Both groups contained patients 
who responded to their respective treatments. A responder was defined as a patient who 
experienced a 30% or greater reduction in their NPS.  There were more responders 
(10/19) in the control group than there were in the treatment group (6/21); but this 
difference was not statistically significant. The authors concluded therefore, that 
according to their results mirocurrent therapy was not superior to placebo for reducing 
pain caused by diabetic neuropathy.7   
 The second study found was conducted by Rae et al8 called The effect of 
microcurrent electrical stimulation on the foot blood circulation and pain of diabetic 
neuropathy and was also published in 2011. This was a small RCT that compared 
microcurrent therapy and walking exercises with walking exercises alone. The treatment 
used was pulsed at “less than 300 microamperes” via special shoes that the patients used 
while doing walking exercises. These exercises were done every day for 4 weeks in both 
groups. Shoes were similar in shape but no current was administered in the placebo 
group. Pain and foot blood circulation values for the two groups were recorded at the 
beginning of the 4 week period and then once at the end.  The authors claim the study 
was double blinded but they failed to explain how the treatment providers were blinded. 
They specify that “…subjects were randomly arranged into an experimental and control 
group to perform a double blind study”.  The process of randomization was not described. 
This study reported a statistically significant difference between the treatment and control 
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groups; with the treatment group showing greater reduction in pain. Pain was measured 
on a 10 point visual analog scale (VAS). The experimental group’s average VAS for pain 
at the start of the study was 6.69 +/- 2.00. After the study it was 3.25+/- 1.73. The control 
group’s average VAS for pain was 7.31 +/- 1.80 at the start of the study and 6.85 +/- 2.11 
after the study. Foot blood circulation was also measured as a primary endpoint and 
showed significant improvement in the treatment group.8   
 The last study by Oyibo et al9 titled Electrical Stimulation therapy through 
stocking electrodes for painful diabetic neuropathy: a double blind, controlled crossover 
study was published in 2003. In this study 30 patients were randomized to have either 50 
microamperes administered each night via stocking electrodes for 6 weeks or a negligible 
5 microamperes administered via identical stockings which acted as the control. 
Randomization was not described. The 5 micro amps were used so the lights on the 
machine would be lit and appear identical to the machines administering the experimental 
dose.  After the first 6 weeks all the patients entered a 4 week non-treatment phase where 
no one wore the stocking electrodes. After the non-treatment phase the patients crossed 
over to have either the control therapy or the treatment therapy for another 6 weeks. 
Sixteen patients did not complete the first 6 week phase. The reasons for withdrawals 
between the two groups were similar. “Intolerable or inconvenient” and “unhelpful” were 
the most common causes of patient withdrawals.  In the control group there were 2 
patients who dropped out because of dermatitis. The remaining 14 patients who 
completed the study were used in the results. Both pain and sleep disturbance were used 
as end points. The treatment phase and the control phase demonstrated significant 
reductions in pain; a 40.1% reduction and a 49.2% reduction, respectively. Based on 
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these results the authors concluded that there was no evidence to support microcurrent 
therapy as being more effective than placebo for reducing pain caused by diabetic 
neuropathy.9 
DISCUSSION 
 The available research on the efficacy of microcurrent therapy in reducing pain 
caused by diabetic neuropathy as compared to placebo, is sparse and of low quality 
(Table I), indicating further research is likely to have a large impact on our estimate of 
the effect of microcurrent therapy for painful diabetic neuropathy.  
 Two of the three studies7,9 showed that microcurrent therapy and placebo 
significantly reduced pain but one was not more efficacious than the other.  The other 
study8 found microcurrent therapy was more efficacious than placebo (Table II). With 
only three low quality studies with conflicting results the question at hand cannot be 
answered with any degree of certainty. The results do indicate a large placebo effect 
which should not be discounted when considering the utility of microcurrent therapy. 
 All studies started the GRADE evaluation with a presumptive rating of high 
because they were all randomized controlled trials. Certain limitations were common to 
all three studies. They all had small population sizes and lacked solid information on 
confidence intervals or had large margins of error. Therefore, all studies were 
downgraded one level for imprecise and underpowered results. Moreover, all of the 
studies recorded pain which is a subjective outcome. Subjective outcomes per se, increase 
the risk of bias. Because pain is an important outcome for patients, no downgrade was 
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made to any study based on its use as an outcome. Downgrades were made for inadequate 
blinding and non-specific methods of collecting the subjective data. The process of 
randomization is not described in any of the studies. While this information would have 
been appreciated, no downgrades were made based on this shortcoming alone. 
 In the study by Gossrau et al7 no significant difference between treatment and 
control was demonstrated. This study was only single blinded and there was not enough 
detail describing the process by which the authors collected the subjective data. The 
questionnaires may have been asked by the authors who would have known which 
treatment each patient received. Due to this increased risk of bias the article was 
downgraded one level for weakness in methodology.  The trial was not stopped early and 
patients were analyzed in the groups to which they were randomized. No downgrade was 
made based on inconsistencies. Although the smoking status of the patients in each group 
is unknown the groups appeared to be similar with respect to other known prognostic 
factors. Next, the study was downgraded another level of evidence for being 
underpowered due to a small sample size of 40 and imprecision because no confidence 
intervals were given. The study started with 41 patients and the results accounted for 40. 
This was either a glaring error in simple mathematics or a failure to follow-up with the 
patient without explanation. A single patient would not have changed the results of the 
study so no downgrade was made based on this weakness.  No publication bias was 
detected. Ultimately the final GRADE of the evidence for this study was deemed to be 
low.  
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 In the study by Rae et al8 microcurrent therapy was found to be significantly more 
efficacious than the control in reducing pain caused by diabetic neuropathy. Thirty two 
subjects began the study and 29 completed it. The 3 that did not, were dropped from the 
study because they failed to continue their daily exercises. No crossover occurred. 
Patients were analyzed in the groups to which they were randomized. The study was not 
downgraded for methodology despite there being some ambiguity regarding the method 
the authors used to blind the providers in order to make the study double blinded.  While 
it would have been nice to know how that was done it is not reason enough to downgrade 
the evidence rating. However, there were some significant issues identified in the article. 
The control and treatment groups may not have been similar with respect to prognostic 
factors. The study only takes into account the age, sex, height and weight. There are some 
confounding variables that might significantly skew the results. For example, it is not 
known how long each person had diabetes. In theory, the control group could have had 
diabetes for much longer on average, which would mean that the extent of the vascular 
damage, and therefore nerve damage would be far greater in the control group than the 
experimental group. With such a small sample size it would not take many patients in the 
control group having diabetes for significantly longer than the treatment patients to 
potentially affect the results. This could have affected both the blood circulation and pain 
intensity. Age plays a similar role. The average age of those in the control group is 
greater than that of those in the experimental group (70.38 and 67.88 years, respectively).  
Logically the more time the vascular system is insulted, the more extensive the damage. 
While the ages may not be significantly different it could tilt the outcomes in favor of the 
experimental group. Smoking incidences in the two groups is not addressed. Smoking is a 
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well known and important risk factor in the development of peripheral vascular disease.  
There were a significantly greater proportion of females in the experimental group. Men 
tend to have a higher incidence of vascular disease than women which could have been 
an important difference between the two groups but the authors do not address it.  Taken 
together the differences between the treatment and control groups could have been 
enough to distort the results in favor of microcurrent therapy. The potential prognostic 
differences represent an important inconsistency and so the study was downgraded one 
level. The study was further downgraded for having a small sample size (n=29) which 
under-powers the results as well as rendering imprecise results. The experimental group’s 
average pain at the start of the study was 6.69 +/- 2.00 and after the treatment it was 
3.25+/- 1.73. With error margins this wide, which also overlap, it is difficult to have 
confidence that there was a significant change. The error margins for the control group 
were even wider which means the opposite could be true for the control group. One 
cannot be sure that the actual difference wasn’t significant in the control group. No 
publication bias was detected. The final GRADE of the evidence for this article is low. 
Overall the study does attempt to answer the key question but the limitations of the study 
provide little confidence in the results. A larger study with a more robust list of 
prognostic factors would help to ensure the treatment and control groups are similar, add 
power to the study, and give a more accurate estimate of the size of the effect that 
microcurrent has on pain caused by diabetic neuropathy. 
 The article by Oyibo et al9 used overnight stocking electrodes to administer the 
microcurrent therapy or placebo therapy. They found both therapies significantly reduced 
pain, and both groups saw a similar reduction in the pain level. The study was a 
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randomized, double blinded, placebo controlled crossover study. Overall the 
methodology was sound, except the design allowed for significant non-compliance which 
warranted a downgrade. Out of a possible 336 hours, the patients who received active 
treatment only wore the stockings for 228 hours and the control group wore them for 248 
hours. This means patients only wore the stockings slightly over 2/3 of the time 
requested. The other two studies ensured that all patients received the assigned treatment 
every time. No carryover effects could be found which would support the idea that the 
study designers successfully used the 4 week non-treatment phase to separate the two 6 
week placebo and treatment phases. No downgrade was made for inconsistencies. Due to 
a small sample size (n=14) and for imprecision as demonstrated by the overlapping 
confidence intervals the study was downgraded another level. The overall GRADE level 
of this study was low. It is important to note the withdrawal rate associated with this 
overnight treatment. It does not compromise the quality of the evidence but it does have 
important clinical implications.  In this study over half of the patients who started the 
study dropped out (16/30). The reason for withdrawals between the two groups were 
similar. “Intolerable or inconvenient “ and “unhelpful” were the most common causes of 
patients withdrawal. The study did not differentiate the intolerable withdrawals from the 
inconvenient withdrawals, which would have been relevant information for providers. 
Using stockings while sleeping at night would be an inconvenience to patients, but 
patients who have hyperesthesia type diabetic neuropathy would certainly consider this 
form of treatment intolerable. In the control group, there were 2 patients who dropped out 
because of dermatitis. The dermatitis is a significant concern because diabetic patients are 
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more prone to infection. Any breakdown in the skin due to chronic irritation or scratching 
would seem to present an unacceptable risk.  
CONCLUSION 
 At this time there is not enough high quality evidence to say with any certainty 
that microcurrent therapy is more efficacious than placebo. The three RCTs7-9 that have 
been performed to date, have been small and have conflicting results. The two studies by 
Gossrau et al7 and Oyibo et al9, that were given GRADE ratings of low, found no 
difference between microcurrent therapy and placebo therapy but found both treatments 
significantly reduced pain caused by diabetic neuropathy. The study by Rae et al8 found 
that microcurrent therapy reduced pain significantly more than placebo but it was also 
given a GRADE rating of low. 
Implications for Practice  
 There is currently no good evidence to show that microcurrent therapy is more 
effective at reducing pain caused by diabetic neuropathy than placebo. That being said, 
there are virtually no adverse side effects associated with microcurrent therapy. In the 
studies reviewed in this analysis most patients received significant benefit from using 
microcurrent therapy and placebo therapy. The value of this perceived affect should not 
be discounted, particularly in patients who are resistant to other treatments or who suffer 
severe side effects from medications.  
 
 
 
18 
 
Implications for Research  
 Microcurrent therapy is imperceptible to humans because it cannot cause nerves 
to fire or muscles to contract. The fact that microcurrent therapy is indistinguishable from 
a placebo treatment makes it an excellent candidate for large RCTs which need to be 
performed before its efficacy can be determined with any certainty. A large well designed 
RCT would carry considerable weight given the small number of low quality studies that 
have been performed to date.  
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Table I. Characteristics of Reviewed Studies 
 
Study Study 
Design 
Sample 
size 
Randomization Concealment Follow-up Quality of Evidence 
(GRADE) 
Gossrau et 
al7 
Randomized 
controlled 
trial 
n=41 Adequate, but 
process not 
described 
Single blinded 8 weeks 
1 lost to 
follow-up 
Low - downgraded for 
lack of concealment and 
sparse/imprecise data 
Rae et al8 Randomized 
controlled 
trial 
n=29 Adequate, but 
process not 
described 
Double blinded 4 weeks 
Complete 
Low - downgraded for 
important inconsistencies 
and sparse/imprecise data 
Oyido et al9 Randomized 
controlled 
trial 
crossover 
n=14 Adequate, but 
process not 
described 
Double blinded 16 weeks 
Complete 
Low – downgraded for 
weakness in methodology 
and sparse/imprecise data 
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Table II. Summary of Findings 
 
Study Treatment Outcome Treatment 
Results 
Control Results Significant 
difference 
between 
MTENS and 
placebo found? 
Gossrau et 
al7 
30 min. in office 
microcurrent on legs 
3x/week for 4 
weeks 
Responder = 30% 
reduction in NPS* 
sum 
6/21* were 
responders 
10/19* were 
responders 
No 
Rae et al8 Microcurrent 
administered via 
shoe while walking 
1 hr/day x 4 weeks 
Pain reduction as 
rated on VAS 
3.44±2.16 0.46±2.47 Yes 
Oyibo et al9 Overnight 
microcurrent via 
stocking electrodes 
nightly for 6 weeks 
Pain as rated on 
VAS 
Tx Initial Pain = 
6.2 (3.9-8.4)  
Tx End Pain = 3.1 
(1.0-5.1) 
Control Initial Pain 
= 7.1 (5.6-8.7) 
Control End Pain 
=3.6 (1.8-6.0) 
No 
* P>0.09, no confidence intervals given 
 
